{"id":34,"date":"2021-01-13T22:00:18","date_gmt":"2021-01-13T21:00:18","guid":{"rendered":"https:\/\/www.ibd-comfort.cz\/?page_id=34"},"modified":"2021-01-29T11:24:46","modified_gmt":"2021-01-29T10:24:46","slug":"protilatky-ustekinumab","status":"publish","type":"page","link":"https:\/\/www.ibd-comfort.cz\/vyzkum\/protilatky-ustekinumab\/","title":{"rendered":"Protil\u00e1tky – ustekinumab"},"content":{"rendered":"\r\n
\r\n\r\n
\r\n
\r\n
\r\n\r\n \r\n
\r\n\r\n
\r\n\r\n
\r\n Vimeo-Free-Videos<\/a> \/ Pixabay <\/div>\r\n \r\n
\r\n
\r\n\r\n
\r\n\r\n \r\n

Protil\u00e1tky
ustekinumab<\/span><\/h1>\r\n \r\n \r\n \r\n \r\n <\/div>\r\n\r\n <\/div>\r\n <\/div>\r\n\r\n \r\n
\r\n\r\n <\/span>\r\n <\/span>\r\n
\r\n <\/span>\r\n \r\n \r\n

Anotace<\/strong><\/h2>\n\n\n\n

Ustekinumab je zcela hum\u00e1nn\u00ed terapeutick\u00e1 monoklon\u00e1ln\u00ed protil\u00e1tka nam\u00ed\u0159en\u00e1 proti podjednotce p40 interleukin\u016f 12 a 23. Jde o nov\u00fd l\u00e9\u010div\u00fd p\u0159\u00edpravek, schv\u00e1len\u00fd k terapii Crohnovy choroby (Crohn\u00b4s disease, CD). Ustekinumab je \u00fa\u010dinn\u00e9 a bezpe\u010dn\u00e9 l\u00e9\u010divo, av\u0161ak n\u00e1klady spojen\u00e9 s terapi\u00ed jsou velmi vysok\u00e9. L\u00e9\u010dba by proto m\u011bla b\u00fdt ide\u00e1ln\u011b nasazov\u00e1na jen tam, kde lze p\u0159edpokl\u00e1dat uspokojiv\u00fd \u00fa\u010dinek, nem\u011bl by b\u00fdt ztr\u00e1cen \u010das a pacienti zat\u011b\u017eov\u00e1ni terapi\u00ed drah\u00fdm prepar\u00e1tem, kter\u00fd nebude efektivn\u00ed a m\u016f\u017ee vyvolat ne\u017e\u00e1douc\u00ed vedlej\u0161\u00ed reakce. Sou\u010dasn\u00e9 mo\u017enosti laboratorn\u00ed diagnostiky p\u0159i predikci \u00fa\u010dinnosti biologick\u00fdch l\u00e9\u010div zahrnuj\u00ed mimo jin\u00e9ho laboratorn\u00ed stanoven\u00ed s\u00e9rov\u00fdch hladin biologick\u00fdch l\u00e9\u010div. Jedn\u00edm z faktor\u016f, kter\u00e9 ovliv\u0148uj\u00ed \u00fasp\u011b\u0161nost biologick\u00e9 l\u00e9\u010dby, je pr\u00e1v\u011b dostate\u010dn\u011b vysok\u00e1 s\u00e9rov\u00e1 hladina terapeutick\u00e9 monoklon\u00e1ln\u00ed protil\u00e1tky. Nemocn\u00ed s detekovatelnou s\u00e9rovou hladinou l\u00e9\u010diva \u010dast\u011bji dosahuj\u00ed setrval\u00e9 terapeutick\u00e9 odpov\u011bdi na biologickou l\u00e9\u010dbu a maj\u00ed m\u00e9n\u011b ne\u017e\u00e1douc\u00edch poinfuzn\u00edch reakc\u00ed ve srovn\u00e1n\u00ed s pacienty s nedetekovatelnou s\u00e9rovou hladinou biologika.<\/p>\n\n\n\n

C\u00edle projektu<\/strong><\/h2>\n\n\n\n
  1. Anal\u00fdza s\u00e9rov\u00fdch hladin ustekinumabu ve vztahu ke klinick\u00fdm, endoskopick\u00fdm a laboratorn\u00edm marker\u016fm CD.<\/li>
  2. Definov\u00e1n\u00ed cut-off s\u00e9rov\u00e9 hladiny ustekinumabu pro induk\u010dn\u00ed a udr\u017eovac\u00ed f\u00e1ze terapie ve vztahu k predikci odpov\u00eddavosti na terapii.<\/li>
  3. Vytvo\u0159en\u00ed biobanky s\u00e9r nemocn\u00fdch l\u00e9\u010den\u00fdch ustekinumabem pro pot\u0159eby dal\u0161\u00edch v\u011bdeck\u00fdch projekt\u016f.<\/li><\/ol>\n\n\n\n

    Metodika v\u00fdzkumu<\/strong><\/h2>\n\n\n\n
    \"Protil\u00e1tky\"<\/a><\/figure><\/div>\n\n\n\n

    Anal\u00fdza klinick\u00fdch, endoskopick\u00fdch a laboratorn\u00edch biomarker\u016f IBD u nemocn\u00fdch, kte\u0159\u00ed byli indikov\u00e1ni k biologick\u00e9 terapii ustekinumabem z d\u016fvodu (a) neodpov\u00eddavosti na standardn\u00ed imunomodula\u010dn\u00ed terapii a\/nebo biologickou terapii anti-TNF-alfa biologick\u00fdmi l\u00e9\u010divy nebo vedolizumabem a (b) kontraindikac\u00ed standardn\u00ed imunomodula\u010dn\u00ed terapie a\/nebo biologick\u00e9 terapie anti-TNF-alfa biologick\u00fdmi l\u00e9\u010divy nebo vedolizumabem. <\/p>\n\n\n\n

    U pacient\u016f budou zm\u011b\u0159eny s\u00e9rov\u00e9 hladiny ustekinumabu p\u0159ed aplikac\u00ed ka\u017ed\u00e9 subkut\u00e1nn\u00ed d\u00e1vky l\u00e9\u010diva v pr\u016fb\u011bhu prvn\u00edho roku terapie (t\u00fdden 8, 16, 24, 32, 40 a 48). Tyto tzv. trough levels ustekinumabu budou korelov\u00e1ny s klinick\u00fdmi charakteristikami nemoci, vyj\u00e1d\u0159en\u00fdmi ve form\u011b Harvey Bradshawova indexu. Z laboratorn\u00edch biomarker\u016f budou sledov\u00e1ny fek\u00e1ln\u00ed kalprotektin a s\u00e9rov\u00fd CRP. Endoskopick\u00fd n\u00e1lez bude hodnocen na konci 1. roku l\u00e9\u010dby ustekinumabem.<\/p>\n","protected":false},"excerpt":{"rendered":"

    S\u00e9rov\u00e9 hladiny ustekinumabu a jejich vztah ke klinick\u00fdm a endoskopick\u00fdm charakteristik\u00e1m idiopatick\u00fdch st\u0159evn\u00edch z\u00e1n\u011bt\u016f u nemocn\u00fdch l\u00e9\u010den\u00fdch monoklon\u00e1ln\u00ed protil\u00e1tkou proti p40. Anotace Ustekinumab je zcela hum\u00e1nn\u00ed terapeutick\u00e1 monoklon\u00e1ln\u00ed protil\u00e1tka nam\u00ed\u0159en\u00e1 proti podjednotce p40 interleukin\u016f 12 a 23. Jde o nov\u00fd…<\/p>\n","protected":false},"author":1,"featured_media":27,"parent":21,"menu_order":16,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-34","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/pages\/34","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/comments?post=34"}],"version-history":[{"count":0,"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/pages\/34\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/pages\/21"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/media\/27"}],"wp:attachment":[{"href":"https:\/\/www.ibd-comfort.cz\/api\/wp\/v2\/media?parent=34"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}